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Abstract: Ischemic stroke is one of the leading causes of long-term disability and death in developed and developing 
countries. As emerging disease, stroke related mortality and morbidity is going to step up in the next decades. This is both 
due to the poor identification of risk factors and persistence of unhealthy habits, as well as to the aging of the population. 
To counteract the estimated increase in stroke incidence, it is of primary importance to identify risk factors, study their ef-
fects, to promote primary and secondary prevention, and to extend the therapeutic repertoire that is currently limited to the 
very first hours after stroke. While epidemiologic studies in the human population are essential to identify emerging risk 
factors, adequate animal models represent a fundamental tool to dissect stroke risk factors to their molecular mechanism 
and to find efficacious therapeutic strategies for this complex multi- factorial disorder. The present review is organized 
into two parts: the first part deals with the animal models that have been developed to study stroke and its related risk fac-
tors and the second part analyzes the specific stroke models. These models represent an indispensable tool to investigate 
the mechanisms of cerebral injury and to develop novel therapies.  
Keywords: Aging, animal model, atherosclerosis, hypercholesterolemia, hyperhomocysteinemia, hypertension, ischemic 
stroke, risk factor. 
INTRODUCTION  
  Stroke represents the leading cause of long-term disabil-
ity and second-frequent cause of mortality among all causes 
of death (behind cardiovascular diseases (CVD)) (National 
Center for Health Statistics, http://www.cdc.gov/nchs/fastats/ 
deaths.htm) [1]. Among noninstitutionalized U.S. adults the 
estimated prevalence of stroke in 2005 was 2.6%, approxi-
mately 5,839,000 persons, being similar among men (2.7%) 
and women (2.5%). It is expected that these numbers will 
dramatically step up in the next years and to increase by al-
most one half by 2020. This is due to the increase in the 
mean population age, the persistence and the increase of un-
healthy life habits, including physical inactivity, tobacco 
smoking, excessive and unhealthy food resulting in obesity, 
arterial hypertension, hypercholesterolemia and type II dia-
betes affecting in particular young patients, in both industri-
alized and developing countries [2] [World Health Organiza-
tion, http://www.who.int/cardiovascular_diseases/resources/ 
atlas/en]. The incidence and prevalence of ischemic stroke, 
together with its long-term consequences account for an es-
timated direct and indirect cost of $65.5 billion in 2008, re-
flecting a mean lifetime cost of a stroke patient of $140,048 
(estimation for the United States) that includes inpatient 
care, rehabilitation and follow-up care [3]. 
  Ischemic stroke accounts for approximately 87% of all 
strokes (10% are intracerebral hemorrhages, and 3% are su-
barachnoid hemorrhages) (National Institute of Neurological 
Disorders and Stroke), resulting from embolic or throm- 
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botic occlusion of a major cerebral artery, most often the 
middle cerebral artery (MCA) or one of its branches. 
  Stroke is a complex disorder precipitated by a variety of 
genetic and environmental factors. The clinical variability of 
stroke, mainly in terms of duration, localization and severity 
of ischemia, as well as the patients’ age and coexisting sys-
temic diseases, poses huge challenges for clinical research, 
as very large patient groups are needed to avoid the con-
founding effects of disease diversity. Although experimental 
longitudinal clinical studies are of major importance for un-
derstanding stroke, having provided strong evidence for the 
existence of genetic and environmental influence factors, 
they are seldom helpful in understanding disease mecha-
nisms and their results can be misleading [4]. On the other 
hand,  in vitro systems alone cannot thoroughly evaluate 
stroke and its consequences, given the importance of the 
brain vasculature to study the effects of abnormal brain per-
fusion and given the involvement of other systems as well 
[5]. For these reasons animal models are required to repro-
duce specific aspects of human disease, to understand the 
complex pathophysiology of stroke and to find efficacious 
preventive and therapeutic approaches [6, 7].  
Experimental animal models encompass today: 
i  Models addressing specific risk factors such as athe-
rosclerosis, hypercholesterolemia, hypertension, hy-
per-homocysteinemia, obesity and aging; 
ii  Models mimicking single-gene disorders associated 
with ischemic stroke, such as cerebral autosomal 
dominant arteriopathy with subcortical infarcts and 
leucoencephalopathy (CADASIL); 
iii  Focal and global cerebral ischemia models that mimic 
specific aspects of human stroke (these models are Part One- Animal Models in Stroke Research  The Open Neurology Journal, 2010, Volume 4    27 
discussed in the second part of the review: “Part two: 
Modeling cerebral ischemia”).  
  The models described in i.) and ii.) are used to study the 
relationship between risk factors (modifiable and not modifi-
able) and stroke with the overall aim to understand and to 
develop efficacious treatments to avoid the occurrence of 
cerebral ischemic damage. In these models, variables can be 
taken under strict control and researchers may address spe-
cific questions about pathologic events leading to stroke [8]. 
MODELS FOR STUDYING STROKE RELATED RISK 
FACTORS 
Atherosclerosis and Associated Risk Factors 
  Atherosclerosis is a chronic inflammatory response of 
arterial blood vessels characterized by intimal lesions called 
fibro-fatty plaques that protrude into the lumen of the vessel, 
weaken the underlying media and undergo a series of com-
plications [9]. Although the process of atherogenesis has 
been thought to consist largely of the accumulation of lipids 
within the arterial wall, the pathophysiology of atherosclero-
sis is more complex.  
  Endothelial dysfunction is the first initiating step. Differ-
ent mechanisms including elevated and modified LDL, hy-
pertension, free radicals as induced by cigarette smoking and 
type II diabetes, genetic alterations elevated plasma levels of 
homocysteine, infective microorganisms and combinations 
of these risk factors can lead to endothelial dysfunction [10, 
11].  
  The damage induced by these factors leads to alterations 
of the intrinsic properties of endothelium. As such, vascular 
permeability and the adhesiveness to leukocytes and platelets 
are increased, and anticoagulant properties are altered.  
  The persistence of irritative cues on endothelial cells 
cause local inflammatory responses that stimulate the migra-
tion and proliferation of smooth- muscle cells leading in the 
long run to the remodeling of the vessel. Characteristic of 
this initial rearrangement in the coronary arteries is that the 
internal diameter of the lumen remains largely unaltered at 
the expense of a dilatation towards outside [12]. In the ca-
rotid arteries the irritative cues on endothelial cells augment 
the intimal-medial wall thickness (IMT), that is a particularly 
relevant marker of subclinical atherosclerosis [13]. 
  The persistent inflammatory reaction attracts more and 
more macrophages and lymphocytes from the blood that 
multiply within the lesion. These monocyte-derived macro-
phages and T lymphocytes induce through the sustained re-
lease of cytokines, chemokines and growth factors, a remod-
eling of the vessel wall together with the proliferation of 
smooth-muscle cells [14]. At a certain point, the advanced 
lesion called “atherosclerotic plaque” protrudes into the lu-
men of the vessel altering blood flow. A fibrous cap overly-
ing a core of lipid core and necrotic tissue is characteristic of 
this plaque.  
  If the plaque spontaneously ruptures blood coagulation is 
locally activated and may cause a complete occlusion of the 
vessel or induce distal thromboembolism [15]. Because athe-
rosclerosis is a multifactorial disease, understanding the un-
derlying genetics and role of environmental factors may help 
to explain differences in susceptibility to agents that cause 
this disease. All the current mouse models of atherosclerosis 
are based on perturbations of lipoprotein metabolism through 
dietary and/or genetic manipulations. The models for athero-
sclerosis will therefore be explained in the section on hyper-
cholesterolemia (a). Nonetheless it is worth considering that 
although hyperlipidemia is necessary for the development of 
atherosclerosis, many nonlipid factors can influence the se-
verity and the characteristics of lesions. 
a. Hypercholesterolemia 
  Deposits of low-density proteins in the arterial walls are 
an important trigger for the development of atherosclerotic 
disease [15]. Despite increased attention towards this risk 
factor and the use of pharmacological treatments to lower 
plasmatic cholesterol levels, atherosclerosis remains one of 
the principal causes of cardiovascular disease [16, 17]. The 
apolipoprotein E-deficient (apoE
-/-) mouse, established in 
1992, is one of the most important animal models of athero-
sclerosis [18] because of its propensity to spontaneously
 de-
velop atheromatous lesions when kept on a cholesterol-rich 
diet. The apoE is an important modulator of lipoprotein in-
teractions with several receptors, including low-density lipo-
protein (LDL) receptors and LDL-related receptor on the 
surface of several lipoproteins, including chylomicrons, 
VLDL and HDL particles [19]. 
 ApoE
-/- mice are characterized by increased plasma cho-
lesterol levels and by the development of accelerated athero-
sclerosis with extensive lipid deposition on major arteries 
such as the aorta [20]. Similar to what has been observed in 
human atherosclerotic plaques apoE
-/- m i c e  a l s o  h a v e  
plaques that are heavily infiltrated by CD4
+ T cells [21]. In 
these mice  atherosclerotic changes of the vessel walls can be 
observed progressively during aging. Intermediate vascular 
lesions containing foam cells and smooth muscle cells can be 
found at 15 weeks, and fibrous plaques appear at 20 weeks 
of age.  
  The atherosclerotic process is further accelerated when   
mice are fed with cholesterol-rich high protein, high carbo- 
hydrate and high fat products, the so-called ‘Western diet’  
[22]. The histological and morphological analysis of plaque  
progression and lesion size share similarities with human   
atherosclerotic lesions [21]. In particular, it has been recently  
described that old apoE
-/- mice develop plaques in the bra- 
chiocephalic arteries that closely resemble human plaques. 
  Murine studies on atherosclerotic lesions are nonetheless 
difficult as cholesterol metabolism, lipid profile, cardiovas-
cular physiology, plaque pathology are different to that of 
humans. Although apoE
-/- mice display vascular atheroscle-
rotic changes they do not develop spontaneous thrombotic 
occlusions and/or embolic events [22]. Despite these limita-
tions of the apoE
-/- mouse, it has been possible to study cho-
lesterol absorption inhibitors such as ezetimibe [23], anti-
hypertensive drugs, such as angiotensinogen converting en-
zyme inhibitors or angiotensin II receptor blockers [24], and 
antidiabetic drugs as rosiglitazone and trogliatiazone [22, 
25]. This demonstrates once again that quite different risk 
factors contribute to plaque formation and that these can be 
addressed therapeutically.  
  Another important animal model in the study of hyper-
cholesterolemia is the Apolipoprotein B (apoB) mouse. 28     The Open Neurology Journal, 2010, Volume 4  Bacigaluppi et al. 
ApoB is the major protein directing the metabolic fate of 
both VLDL and LDL, and its increased plasma concentra-
tions are associated with the development of cardiovascular 
diseases. The transgenic apoB mice that express human 
apoB have similar plasma concentrations to those of normol-
ipidemic humans when fed on normal diet [26]. However 
when these mice are fed with the typical 'Western Diet' pro-
nounced atherosclerosis develops with a higher extent in 
C57BL/6 female mice than males. Macrophage foam cells 
characterize primarily the atherosclerotic lesions that form 
[27]. 
 While  in  humans the deficiency of LDL receptors 
(LDLR) leads to a dramatic phenotype of pronounced hyper-
cholesterolemia with catastrophic clinical consequences, 
mice lacking the LDL receptor (LDLR
-/-) display only a 
modest hypercholesterolemia when fed on a normal diet   
[28]. As in the other model of hypercholesterolemia (apoE 
or apoB mice) also these mice develop atherosclerosis on the 
Western type diet. The lesions formed in these mice are of 
simple morphology and predominantly consist of lipid-laden 
macrophages [29]. 
  A key component to the formation of the atherosclerotic 
lesion, which involves an inflammatory process, has also 
been studied extensively and targeted with various anti- in-
flammatory drugs (acetylsalicylic acid, sulindac, celecoxib) 
[30-32]. Mixed results on plaque size and progression have 
been observed in these studies and up to now it is not en-
tirely clear whether anti-inflammatory drugs may have a 
beneficial role on the atherosclerotic plaque in humans [22].  
  Other experimental studies on atherosclerosis have used 
the apoE
-/- mouse as starting basis for double knockout mice 
or transgene to study genes involved in lipid metabolism 
(e.g. acyl CoA cholesterol acyl transferase-2 [33], ATP bind-
ing cassette (ABC) transporter ABCA1 [34], low density 
lipoprotein receptor [35]), inflammation (e.g. C-reactive pro-
tein [36], inducible nitric oxide synthase (iNOS) [37], endo-
thelial nitric oxide synthase (eNOS)[38], interleukin-1 beta 
[39]) and blood hemostasis (e.g. fibrinogen [40], plasmino-
gen [41], plasminogen activator inhibitor-1 [42]). See also 
reference  [43] for an extensive review on atherosclerosis 
mouse models. 
b. Modeling Arterial Hypertension 
  Arterial hypertension, defined as untreated systolic pres-
sure of 140 mmHg, diastolic pressure of 90 mmHg or pre-
scription of antihypertensive drugs, affects nearly one in 
three adults in the United States. Blood pressure, particularly 
systolic blood pressure, increases with age [44]. Hyperten-
sion can be subdivided into two main categories: primary 
hypertension and secondary hypertension. Primary, essential 
or idiopathic hypertension is assumed when no specific 
cause can be found. In secondary hypertension, elevated 
blood pressure levels are due to specific reasons (most often 
renal dysfunction, hormone alterations and/or sleep apnea) 
that if identified can be corrected [45]. 
  Hypertension is the most important risk factor for stroke 
and a direct correlation between blood pressure values and 
stroke risk has been described [46, 47]. Subjects with blood 
pressure lower than 120/80 mmHg have about half the life-
time risk of stroke compared to subjects with higher blood 
pressure [48]. The relationship between blood pressure and 
cardiovascular risk is considered to be continuous, consistent 
and independent of other risk factors. [49].  
  Although recent advances in blood pressure control (data 
from the National Health and Nutrition Examination Survey, 
NHANES 1999–2004) showed that of  the subjects with 
hypertension aged 18 and older, 71.8% were aware of their 
condition, only 61.4% were under current treatment and 
35.1% had arterial pressure levels that were reasonably con-
trolled (data from National Center for Health Statistics and 
National Heart, Lung and Blood Institute). Because of the 
high prevalence of hypertension and its high direct and indi-
rect costs (estimated to be of $69.4 billion for 2008) identify-
ing genetic and environmental risk factors is not only impor-
tant for the prevention of CVD but also for the development 
of new pharmacological tools aimed at preventing late com-
plications [50].  
  Over the past 50 years various animal models of hyper-
tension have been developed, predominantly in the rat. Dif-
ferent rat models can either be grouped according to their 
capacity to mimic the etiology of hypertension (primary vs. 
secondary and genetic vs. environmental) or according to the 
resulting end-organ damage, cardiac failure vs. renal failure 
vs. vascular injury. With the use of these models, analysis of 
genetic susceptibility factors to multifactor diseases has be-
come feasible as animal studies avoid (1) genetic heteroge-
neity, (2) environmental noise, and (3) the poor statistical 
power related to small patient populations [51]. 
  Spontaneously hypertensive rats (SHR) represent the 
animal model most widely used in hypertension studies. 
They mimic in particular the human form of primary hyper-
tension although the Mendelian type of inheritance that char-
acterizes hypertension in the SHR is rarely encountered in 
humans. Okakamoto and Aoki [52] obtained the SHR rats by 
inbreeding Wistar rats showing the highest blood pressure. 
These animals develop increases in blood pressure beginning 
at six to seven weeks of age and reach a stable level of hy-
pertension (reach systolic blood pressures of 180- 200 
mmHg) by 17 to 19 weeks.  
  The SHR develop many features of hypertensive end- 
organ damage as cardiac hypertrophy, present in 30% of   
cases [53], heart failure present in 60% of the rats at the age  
of 18- 24 months, renal proteinuria, decreased creatinine   
clearance as signs of renal dysfunction [54, 55]. However,  
they do not exhibit gross vascular problems, apart from con- 
sistently impaired endothelium relaxation [56]. They have no  
tendency to develop strokes, macroscopic atherosclerosis or  
vascular thrombosis. Mean survival of this strain is of 10- 21  
months. Interestingly various anti-hypertensive drugs like   
calcium antagonists, inhibitors of the renin- angiotensin sys- 
tem and direct vasodilators can lower consistently blood   
pressure in the SHR strain. However end organ damage   
seems not to be prevented by any kind of treatment [57].  
  Another strain, the spontaneous hypertensive stroke 
prone rat(SHR-SP) exhibits an early onset of hypertension, 
and 80% of animals experience stroke between 9 and 13 
months of age [58]. There are many pathogenetic similarities 
between strokes in SHR-SP rats and humans [59]. On the 
SHR-SP, it was in fact possible to identify one of the genetic 
components responsible for large infarct volumes in re-
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pressure values. The genes encoding atrial and brain natri-
uretic factor were identified in this case. These genes have 
well- established vasoactive properties and might be in-
volved in the control of vasoreactivity, growth and remodel-
ing of cerebral vessels [60]. 
  Further, the SHR-SP exhibits salt-sensitivity, increased 
vascular release of super oxide and decreased total plasma 
antioxidant capacity. The super oxide release in the SHR-SP 
rats has been found to inactivate nitric oxide in mesenteric 
arteries and to be directly correlated with hypertension. In-
terestingly, administration of super oxide dismutase (SOD) 
returns the bioactive nitric oxide levels to normal together 
with blood pressure [61]. These data suggest that oxidative 
stress plays an important role in severe hypertension in salt-
loaded SHR-SP rats and its associated vascular damage [62]. 
  To help to clarify the role of individual genes, other ani-
mal models of hypertension were developed. The transgenic 
rat overexpressing the mouse Ren-2 gene ((TGR-
mREN2)27) is important in hypertension research as, in con-
trast to the SHR and SHR-SP rat, it is a genetically inherited 
form of hypertension for which the responsible gene is 
known. Nonetheless the exact mechanism via  which this 
mutation leads to hypertension is not clear. That hyperten-
sion usually depends not on a single candidate gene but on a 
variety of genes can be clearly shown by the fact that the 
severity of hypertension in (TGR-mREN2)27 rats is depend-
ent on the genetic background. For example, Sprague- 
Dawley rats develop an accelerated and more malignant hy-
pertension compared with Lewis rats that do not develop 
hypertension [63].  
  A further animal model of primary genetic hypertension 
is the Dahl salt- sensitive rat. This rat develops severe and 
fatal hypertension when it receives a high salt diet. The in-
creased sensitivity to salt is also present when these rats are 
fed with normal diet as they also develop hypertension. Ge-
netic analysis has revealed a role for the angiotensin convert-
ing enzyme (ACE) and atrial natriuretic factor (ANP) recep-
tor genes. Cardiac hypertrophy develops in about 32% of rats 
and cardiac heart failure evolves early after its onset (about 
4-5 months of age) [64, 65]. 
  To model secondary renal hypertension in the rat the 
most used method is to occlude the renal artery with a clip, 
leaving either the controlateral kidney intact (‘two-kidneys 
one-clip’) or removing this second kidney (‘one-kidney one-
clip) [66, 67]. Although clipping of the renal artery has also 
been used in the dog, the rat model is much more reliable. In 
the rat model, like in human disease, hypertension is chronic, 
while in the dog the rapid formation of vessel collaterals 
accounts for its short duration. Cardiac hypertrophy that af-
fects approximately 25-50% of rats subjected to the clipping 
can be attenuated by administration of renin- angiotensin 
inhibitors and calcium antagonists, but diuretics and beta-
blockers are not effective. As such, animal models of hyper-
tension offer the opportunity to investigate not only the 
pathophysiology of hypertension, but also to the effects of 
anti-hypertensive drugs. Further, they can be used for induc-
ing stroke, as has been made with the SHR-SP rat, to study 
the complex vascular response that follows stroke [60, 68]. 
 
c. Hyperhomocysteinemia 
  High levels of plasma homocysteine represent a relevant 
risk factor for cardiovascular disease, stroke, and venous 
thromboembolism [69, 70]. Although severe forms of hyper-
homocysteinemia (plasma concentrations above 100 mol  
L
-1) may result from mutations of enzymes involved in the 
metabolism of homocysteine such as cystathionine -
synthetase (CBS) or 5,10-methylenetetrahydrofolate reduc-
tase (MTHFR), also the deficiency of cofactors (folic acid, 
vitamin B6 and B12) can result in the mild forms of hyper-
homocysteinemia characterized by a plasma concentration of 
12–50 mol L
-1. Patients affected by severe forms of hyper-
homocysteinemia have, if untreated, 50% of chance of de-
veloping a major vascular event (myocardial infarction, 
stroke, or venous thromboembolism) before the age of 30 
years [71].  
  Also mild hyperhomocysteinemia, as pointed out by re-
cent epidemiological studies, is considered as a risk factor 
for stroke, cardiovascular disease, and venous thromboem-
bolism [72].  
  The underlying pathophysiological mechanism of hyper-
homocysteinemia has been suggested to be enhanced 
atherothrombosis. Homocysteine causes in fact endothelial 
cell dysfunction and induces apoptosis in endothelial and 
smooth muscle cells. The strongest evidence that homocys-
teine plays a causative role in atherothrombosis has been 
gained from studies of hyperhomocysteinemia in animal 
models in the last ten years.  
  The first genetic model of hyperhomocysteinemia in 
mice was developed in 1995 through targeted disruption of 
the CBS gene thereby establishing a severe form of hyper-
homocysteinemia induced by homozygous CBS-deficiency 
(plasma levels of homocysteine elevated by 40-fold with 
plasma concentrations above 200 mol L
-1) and a mild form 
in heterozygous CBS deficiency (plasma concentration 6-15 
mol L
-1) [73]. Severe growth retardation, hepatic steatosis 
and dislocation of the lens are characteristics of the homozy-
gous mouse model. Very similar clinical features character-
ize also the natural history of patients with homocystinuria 
[74]. On the other hand, heterozygous mice with twice the 
normal plasmatic homocysteine levels are apparently 
healthy, thereby making them interesting models for study-
ing mild forms of hyperhomocysteinemia. Notably heterozy-
gous CBS- deficient mice display endothelial dysfunctions 
but do not show increased risk for atherosclerotic plaque 
formation [73].  
  Another model of hyperhomocysteinemia is the MTHFR-
deficient mouse. In contrast to the CBS-deficient mouse, 
heterozygous and homozygous MTHGR-deficient animals 
show early atherosclerotic lesions. Despite the presence of 
atherosclerotic plaques, these mice do not exhibit increased 
lipid plasma levels, thereby suggesting that hyperhomocys-
teinemia contributes indirectly to the development of athero-
sclerosis [75]. 
  In atherosclerosis prone animals like apoE
-/- mice, hyper-
homocysteinemia accelerates the development of atheroscle-
rosis through the enhanced expression of inflammatory me-
diators (e.g. receptor for advanced glycation end products 
(RAGE), vascular cell adhesion molecule-1 (VCAM-1),   
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tissue factor (TF), and matrix metalloproteinase-9 (MMP-9) 
[76]) and by the dysregulation of lipid metabolism [77]. A 
major goal of current research using these animal models is 
to uncover the molecular and cellular mechanisms underly-
ing the atherogenic effects of hyperhomocysteinemia and to 
develop efficacious treatments for lowering the increased 
risk of hyperhomocysteinemic patients [78, 79]. In fact, al-
though today the homocysteine level can be reduced through 
adequate diet, no proof is available that lowering mild ele-
vated homocysteine levels as primary prevention decreases 
the cerebro- or cardiovascular risk. (The Heart Outcomes 
Prevention Evaluation, HOPE 2 Investigators 2006) [80]. 
Also in the secondary prevention for stroke there are cur-
rently no recommendations to treat elevated homocysteine 
levels with vitamins or folic acid [81, 82]. We hope that the 
large Australian study (VITATOPS) in the next few years 
with their data together with increased insight in the patho-
genesis of hyperhomocysteinemia will make the image 
round. 
Aging as Risk Factor for Stroke 
  Age accounts for a so-called not modifiable risk factor 
for stroke. The probability of having a stroke in fact ap-
proximately doubles for each decade of life after age 55. 
(National Center for Health Statistics, http://www.cdc.gov/ 
nchs/fastats/deaths.htm) 
  Rats and mice are the species of choice for most animal 
studies on aging. Most rodents used in aging studies must be 
cared for and maintained for 2 or more years before they can 
be used in experiments therefore requiring considerable fi-
nancial investment [83]. 
  Other animal models for aging include different strains of 
the senescence-accelerated mice (SAM) that by the age of 6 
months undergo significant aging changes as senile amyloi-
dosis, deficits in learning and memory, senile osteoporosis 
together with various neoplastic diseases [84-86]. 
Single-Gene Disorders Associated with Stroke:   
CADASIL 
  Cerebral Autosomal Dominant Arteriopathy with Subcor-
tical Infarcts and Leukoencephalopathy, CADASIL, is a 
heritable small-vessel disease caused by mutations in 
NOTCH3 [87]. Clinically CADASIL comprises recurrent 
strokes and transient ischemic attacks, progressive cognitive 
impairment, and psychiatric disturbance with onset usually 
in the third to sixth decade. The bilateral involvement of the 
anterior temporal white matter and external capsule is a 
characteristic feature in CADASIL [88]. Pathological ex-
amination reveals multiple small, deep cerebral infarcts, leu-
koencephalopathy and a non-atherosclerotic, non-amyloid 
angiopathy of the small cerebral arteries caused by the de-
generation of vascular smooth muscle cells and abnormal 
accumulation of electron dense granular material [89].  
  Recently a transgenic mouse model for CADASIL has 
been developed in which the full-length human Notch3 car-
rying the Arg90Cys mutation is expressed under the SM22 
promoter in vascular smooth muscle cells [90]. Although 
transgenic mice showed no evidence of prominent brain pa-
renchyma damage, both cerebral and peripheral arteries were 
demonstrated to contain granular material deposits and 
Notch3 accumulation typical of CADASIL. This animal 
model will hopefully enable to better understand the underly-
ing mechanisms of this often devastating illness. 
  Animal models for stroke risk factors discussed have 
been summarized in Table 1. 
CONCLUSION 
  This article provides a review of many (but not all) mod-
els for stroke risk factors currently in use. The use of one of 
these models offer an opportunity to investigate mechanisms, 
prevention, and treatment of specific risk factors that are 
related to stroke. Further the effects of genes, gene products, 
and proteins in the development of vascular damage can be 
Table 1.  Animal Models for Studying Risk Factors and Therapies for Stroke 
 
Model for  Model name  Animal species available  Gene/s involved 
Hypercholesterolemia  ApoE deficient mouse  Mouse  ApoE 
  ApoB mutant mouse  Mouse  ApoB 
  LDLR deficient mouse  Mouse  LDLR 
Hyperhomocysteinemia  CBS deficient mouse  Mouse  CBS 
  MTHFR deficient mouse  Mouse  MTHFR 
Primary hypertension  SHR  Rat  Gene not known 
  SHR-SP  Rat  Gene not known 
  Ren-2 transgenic rat (TGR-mREN2)27  Rat  Ren-2 
  Dahl sensitive rat  Rat  ACE and ANF 
Secondary hypertension  Two- kidney one clip  Dog, rat, mouse  - 
  One- kidney one clip  Dog, rat, mouse  - 
Age  Spontaneously aged (> 18 months)  Rat, mouse  - 
  Senescence-accelerated mice  Mouse  Genes not known 
CADASIL  CADASIL transgenic mouse  Mouse  Notch 3 
Abbreviations: ApoE, apolipoprotein E; ApoB, apolipoproteinB; LDLR, Low density lipoprotein receptor; CBS, Cystathionine beta- synthetase; MTHFR, Methylenetetrahydrofolate 
reductase; SHR, Spontaneously hypertensive rat; SHR-SP, Spontaneously hypertensive rat- stroke prone; ACE, Angiotension converting exzyme; ANF, atrial natriuretic factor; 
CADASIL, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Part One- Animal Models in Stroke Research  The Open Neurology Journal, 2010, Volume 4    31 
determined. However, no model is able to mimic and de-
scribe human stroke: different models are in fact of great 
value in modeling the different risk factors and aspects of 
human disease. The choice of using one model rather than 
another depends essentially on the target of the investigation. 
Nonetheless it is often useful to evaluate more than one 
model in different species to overcome limitations of single 
models. Future development foresee the development of new 
models for risk factors, the more extended use of genetic 
manipulation for designing new models. This with the aim of 
creating more and more tools for a better understanding and 
mimicry of stroke related risk factors. At present in fact no 
stroke model is really able to mimic vessel disease that is a 
major cause of disability and mortality in the older popula-
tion.  
  It must also be critically mentioned that until the present 
stage, not many experimental stroke studies made use of the 
pool of transgenic animals at vascular risk that were de-
scribed in this review. Future studies should consider more 
and more the use of aged animals where prolonged arterial 
injury and a generalized aging of all the tissues better mimics 
human stroke. 
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